Boston Scientific Corporation
NYQ: BSXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Boston Scientific Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get BSX Z-Score →About Boston Scientific Corporation
Healthcare
Medical Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
📊 Fundamental Analysis
Boston Scientific Corporation demonstrates a healthy profit margin of 14.4%.
The company recently reported 15.9% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 12.4%, which suggests room for improvement in capital utilization.
At a current price of $61.79, BSX currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $60.59 - $109.50).
💰 Valuation Insight
BSX is valued broadly in line with the sector at a PE of 31.85. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$91.83B
Trailing P/E
31.85
Forward P/E
15.84
Beta (5Y)
0.78
52W High
$109.50
52W Low
$60.59
Avg Volume
16.87M
Day High
Day Low